Epigenetic drugs as immunomodulators for combination therapies in solid tumors

Pharmacology and Therapeutics

Volumn 142, Issue 3, 2014, Pages 339-350

  Sigalotti, Luca ^a   Fratta, Elisabetta ^a   Coral, Sandra ^b   Maio, Michele ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

DNA methylation; Histone post translational modifications; Immunostimulatory antibodies; Immunotherapy

Indexed keywords

4 PHENYLBUTYRIC ACID; 5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; CYTIDINE; DNA METHYLTRANSFERASE; ENTINOSTAT; FK 288; HISTONE DEACETYLASE; IMMUNOMODULATING AGENT; MG 98; MOCETINOSTAT; PANOBINOSTAT; TRICHOSTATIN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALPROIC ACID; ZEBULARINE; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CANCER CELL; CANCER IMMUNOTHERAPY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LONG TERM SURVIVAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; ANIMAL; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; RNA EDITING;

ANIMALS; ANTIGEN PRESENTATION; EPIGENESIS, GENETIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; RNA EDITING;

EID: 84898893534     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.12.015     Document Type: Review

References (145)

1. S.J. Adair, and K.T. Hogan Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules Cancer Immunol Immunother 58 2009 589 601
2. R.J. Amato Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy Clin Genitourin Cancer 5 2007 422 426 (Pubitemid 351219694)
3. S. Amatori, I. Bagaloni, B. Donati, and M. Fanelli DNA demethylating antineoplastic strategies: a comparative point of view Genes Cancer 1 2010 197 209
4. S. Armeanu, M. Bitzer, U.M. Lauer, S. Venturelli, A. Pathil, and M. Krusch et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate Cancer Res 65 2005 6321 6329 (Pubitemid 40994418)
5. J.M. Arnold, M. Cummings, D. Purdie, and G. Chenevix-Trench Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas Br J Cancer 85 2001 1351 1358 (Pubitemid 33081932)
6. P.A. Ascierto, F.M. Marincola, and A. Ribas Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application J Transl Med 9 2011 196
7. S.I. Bae, V. Cheriyath, B.S. Jacobs, F.J. Reu, and E.C. Borden Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL Oncogene 27 2008 490 498
8. L. Bao, K. Dunham, and K. Lucas MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing Cancer Immunol Immunother 60 2011 1299 1307
9. D. Berghuis, M.W. Schilham, H.I. Vos, S.J. Santos, S. Kloess, and E.P. Buddingh et al. Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis Clinical sarcoma research 2 2012 8
10. E.M. Bertino, and G.A. Otterson Romidepsin: a novel histone deacetylase inhibitor for cancer Expert Opin Investig Drugs 20 2011 1151 1158
11. B. Brueckner, R. Garcia Boy, P. Siedlecki, T. Musch, H.C. Kliem, and P. Zielenkiewicz et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases Cancer Res 65 2005 6305 6311 (Pubitemid 40994416)
12. J. Bukur, S. Jasinski, and B. Seliger The role of classical and non-classical HLA class I antigens in human tumors Semin Cancer Biol 22 2012 350 358
13. L. Buonaguro, A. Petrizzo, M.L. Tornesello, and F.M. Buonaguro Translating tumor antigens into cancer vaccines Clin Vaccine Immunol 18 2011 23 34
14. A. Chavez-Blanco, E. De la Cruz-Hernandez, G.I. Dominguez, O. Rodriguez-Cortez, B. Alatorre, and E. Perez-Cardenas et al. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate Int J Oncol 39 2011 1491 1499
15. P. Cheung, and P. Lau Epigenetic regulation by histone methylation and histone variants Mol Endocrinol 19 2005 563 573 (Pubitemid 40349431)
16. S.D. Chou, A.N. Khan, W.J. Magner, and T.B. Tomasi Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells Int Immunol 17 2005 1483 1494 (Pubitemid 41631324)
17. J. Chou, L.N. Voong, C.L. Mortales, A.M. Towlerton, S.M. Pollack, and X. Chen et al. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer J Immunother 35 2012 131 141
18. A.J. Christiansen, A. West, K.M. Banks, N.M. Haynes, M.W. Teng, and M.J. Smyth et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies Proc Natl Acad Sci U S A 108 2011 4141 4146
19. S. Coral, A. Covre, H.J. Nicolay, G. Parisi, A. Rizzo, and F. Colizzi et al. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications Br J Cancer 107 2012 1116 1124
20. S. Coral, G. Parisi, H.J. Nicolay, F. Colizzi, R. Danielli, and E. Fratta et al. Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine- containing demethylating dinucleotide Cancer Immunol Immunother 62 2013 605 614
21. S. Coral, L. Sigalotti, M. Altomonte, A. Engelsberg, F. Colizzi, and I. Cattarossi et al. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications Clin Cancer Res 8 2002 2690 2695 (Pubitemid 34856358)
22. S. Coral, L. Sigalotti, F. Colizzi, A. Spessotto, G. Nardi, and E. Cortini et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications J Cell Physiol 207 2006 58 66
23. S. Coral, L. Sigalotti, A. Covre, H.J. Nicolay, P.G. Natali, and M. Maio 5-AZA-2′-deoxycytidine in cancer immunotherapy: a mouse to man story Cancer Res 67 2007 2900 2901 (author reply 2901-2902) (Pubitemid 46548983)
24. S. Coral, L. Sigalotti, A. Gasparollo, I. Cattarossi, A. Visintin, and A. Cattelan et al. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR) J Immunother 22 1999 16 24 (Pubitemid 29042286)
25. M. Croce, A. De Ambrosis, M.V. Corrias, V. Pistoia, M. Occhino, and R. Meazza et al. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells Oncogene 22 2003 7848 7857 (Pubitemid 37485544)
26. K.A. Cycon, K. Mulvaney, L.M. Rimsza, D. Persky, and S.P. Murphy Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma Immunology 140 2013 259 272
27. C. De Smet, O. De Backer, I. Faraoni, C. Lurquin, F. Brasseur, and T. Boon The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation Proc Natl Acad Sci U S A 93 1996 7149 7153 (Pubitemid 26243517)
28. C. De Smet, C. Lurquin, B. Lethe, V. Martelange, and T. Boon DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter Mol Cell Biol 19 1999 7327 7335 (Pubitemid 29493396)
29. A.M. Di Giacomo, L. Calabro, R. Danielli, E. Fonsatti, E. Bertocci, and I. Pesce et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme Cancer Immunol Immunother 62 2013 1021 1028
30. M. Ehrlich DNA methylation in cancer: too much, but also too little Oncogene 21 2002 5400 5413 (Pubitemid 34983477)
31. M. Ehrlich DNA hypomethylation in cancer cells Epigenomics 1 2009 239 259
32. P.O. Esteve, H.G. Chin, J. Benner, G.R. Feehery, M. Samaranayake, and G.A. Horwitz et al. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells Proc Natl Acad Sci U S A 106 2009 5076 5081
33. M.Z. Fang, Y. Wang, N. Ai, Z. Hou, Y. Sun, and H. Lu et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines Cancer Res 63 2003 7563 7570 (Pubitemid 37466673)
34. A.P. Feinberg, R. Ohlsson, and S. Henikoff The epigenetic progenitor origin of human cancer Nat Rev Genet 7 2006 21 33 (Pubitemid 41828945)
35. N. Fiegler, S. Textor, A. Arnold, A. Rolle, I. Oehme, and K. Breuhahn et al. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells Blood 122 2013 684 693
36. E. Fonsatti, H.J. Nicolay, L. Sigalotti, L. Calabro, L. Pezzani, and F. Colizzi et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications Clin Cancer Res 13 2007 3333 3338 (Pubitemid 46944920)
37. E. Fonsatti, L. Sigalotti, S. Coral, F. Colizzi, M. Altomonte, and M. Maio Methylation-regulated expression of HLA class I antigens in melanoma Int J Cancer 105 2003 430 431 (author reply 432-433) (Pubitemid 36570059)
38. E. Fratta, S. Coral, A. Covre, G. Parisi, F. Colizzi, and R. Danielli et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential Mol Oncol 5 2011 164 182
39. E. Fratta, L. Sigalotti, F. Colizzi, A. Covre, H.J. Nicolay, and R. Danielli et al. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma J Cell Physiol 223 2010 352 358
40. J.S. Garcia, N. Jain, and L.A. Godley An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes OncoTargets and therapy 3 2010 1 13
41. R. Garzon, S. Liu, M. Fabbri, Z. Liu, C.E. Heaphy, and E. Callegari et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1 Blood 113 2009 6411 6418
42. M. Gialitakis, A. Kretsovali, C. Spilianakis, L. Kravariti, J. Mages, and R. Hoffmann et al. Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A Nucleic Acids Res 34 2006 765 772 (Pubitemid 43380662)
43. A.M. Gillenwater, M. Zhong, and R. Lotan Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells Mol Cancer Ther 6 2007 2967 2975 (Pubitemid 350206775)
44. J.A. Gollob, C.J. Sciambi, B.L. Peterson, T. Richmond, M. Thoreson, and K. Moran et al. Phase I trial of sequential low-dose 5-aza-2′- deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma Clin Cancer Res 12 2006 4619 4627 (Pubitemid 44297813)
45. O. Goodyear, A. Agathanggelou, I. Novitzky-Basso, S. Siddique, T. McSkeane, and G. Ryan et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 116 2010 1908 1918
46. Z.S. Guo, J.A. Hong, K.R. Irvine, G.A. Chen, P.J. Spiess, and Y. Liu et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model Cancer Res 66 2006 1105 1113 (Pubitemid 43165979)
47. M. Hanada, D. Delia, A. Aiello, E. Stadtmauer, and J.C. Reed bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia Blood 82 1993 1820 1828 (Pubitemid 23278773)
48. H. Hashimoto, P.M. Vertino, and X. Cheng Molecular coupling of DNA methylation and histone methylation Epigenomics 2 2010 657 669
49. A. Hasim, M. Abudula, R. Aimiduo, J.Q. Ma, Z. Jiao, and G. Akula et al. Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women PLoS One 7 2012 e44952
50. E. Horing, O. Podlech, B. Silkenstedt, I.A. Rota, E. Adamopoulou, and U. Naumann The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells Anticancer Res 33 2013 1351 1360
51. G. Howard, R. Eiges, F. Gaudet, R. Jaenisch, and A. Eden Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice Oncogene 27 2008 404 408
52. A.R. Jazirehi, and D. Arle Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance Am J Clin Exp Immunol 2 2013 55 74
53. Q. Jiang, H.Y. Pan, D.X. Ye, P. Zhang, L.P. Zhong, and Z.Y. Zhang Downregulation of tapasin expression in primary human oral squamous cell carcinoma: association with clinical outcome Tumour Biol 31 2010 451 459
54. R. Juttermann, E. Li, and R. Jaenisch Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation Proc Natl Acad Sci U S A 91 1994 11797 11801
55. A. Kalbasi, E. Fonsatti, P.G. Natali, M. Altomonte, E. Bertocci, and O. Cutaia et al. CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893 J Immunother 33 2010 810 816
56. T. Kanaseki, H. Ikeda, Y. Takamura, M. Toyota, Y. Hirohashi, and T. Tokino et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas J Immunol 170 2003 4980 4985 (Pubitemid 36554727)
57. A.N. Khan, C.J. Gregorie, and T.B. Tomasi Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells Cancer Immunol Immunother 57 2008 647 654
58. H.R. Kim, E.J. Kim, S.H. Yang, E.T. Jeong, C. Park, and J.H. Lee et al. Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway? Exp Mol Med 38 2006 616 624 (Pubitemid 46103583)
59. H. Kitamura, T. Torigoe, H. Asanuma, I. Honma, N. Sato, and T. Tsukamoto Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition J Urol 178 2007 692 696 (Pubitemid 47030489)
60. R.B. Klisovic, W. Stock, S. Cataland, M.I. Klisovic, S. Liu, and W. Blum et al. A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia Clin Cancer Res 14 2008 2444 2449 (Pubitemid 351551079)
61. K.L. Knutson, and M.L. Disis Tumor antigen-specific T helper cells in cancer immunity and immunotherapy Cancer Immunol Immunother 54 2005 721 728 (Pubitemid 40977140)
62. V.V. Konkankit, W. Kim, R.C. Koya, A. Eskin, M.A. Dam, and S. Nelson et al. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway J Transl Med 9 2011 192
63. N.V. Koshkina, K. Rao-Bindal, and E.S. Kleinerman Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases Cancer 117 2011 3457 3467
64. K. Kozar, R. Kaminski, T. Switaj, T. Oldak, E. Machaj, and P.J. Wysocki et al. Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2′-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice Clin Cancer Res 9 2003 3124 3133 (Pubitemid 36993275)
65. G. Kroemer, L. Galluzzi, O. Kepp, and L. Zitvogel Immunogenic cell death in cancer therapy Annu Rev Immunol 31 2013 51 72
66. E. Lech-Maranda, E. Robak, A. Korycka, and T. Robak Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity Mini Rev Med Chem 7 2007 1062 1069 (Pubitemid 47554775)
67. B. Lehnertz, Y. Ueda, A.A. Derijck, U. Braunschweig, L. Perez-Burgos, and S. Kubicek et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin Curr Biol 13 2003 1192 1200 (Pubitemid 36872941)
68. P.A. Link, O. Gangisetty, S.R. James, A. Woloszynska-Read, M. Tachibana, and Y. Shinkai et al. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells Mol Cancer Res 7 2009 851 862
69. P. Londhe, B. Zhu, J. Abraham, C. Keller, and J. Davie CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells Int J Cancer 131 2012 E437 E448
70. A. Lopez-Soto, A.R. Folgueras, E. Seto, and S. Gonzalez HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer Oncogene 28 2009 2370 2382
71. A. Loriot, E. De Plaen, T. Boon, and C. De Smet Transient down-regulation of DNMT1 methyltransferase leads to activation and stable hypomethylation of MAGE-A1 in melanoma cells J Biol Chem 281 2006 10118 10126 (Pubitemid 43864547)
72. A. Lundqvist, S.I. Abrams, D.S. Schrump, G. Alvarez, D. Suffredini, and M. Berg et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity Cancer Res 66 2006 7317 7325 (Pubitemid 44197714)
73. W. Luo, X. Wang, T. Kageshita, S. Wakasugi, A.R. Karpf, and S. Ferrone Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells Oncogene 25 2006 2873 2884 (Pubitemid 43739237)
74. W.J. Magner, A.L. Kazim, C. Stewart, M.A. Romano, G. Catalano, and C. Grande et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors J Immunol 165 2000 7017 7024 (Pubitemid 32001174)
75. B.S. Mann, J.R. Johnson, M.H. Cohen, R. Justice, and R. Pazdur FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247 1252 (Pubitemid 350106355)
76. P.A. Marks, and R. Breslow Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat Biotechnol 25 2007 84 90 (Pubitemid 46087907)
77. N.B. Marshall, and S.L. Swain Cytotoxic CD4 T cells in antiviral immunity J Biomed Biotechnol 2011 2011 954602
78. M. Meissner, T.L. Whiteside, P. van Kuik-Romein, E.M. Valesky, P.J. van den Elsen, and R. Kaufmann et al. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation Br J Dermatol 158 2008 930 940 (Pubitemid 351521434)
79. C. Mengus, E. Schultz-Thater, J. Coulot, Z. Kastelan, E. Goluza, and M. Coric et al. MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas Int J Cancer 132 2013 2459 2463
80. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38 51 (Pubitemid 43054973)
81. A. Mittelman, Z.J. Chen, H. Yang, G.Y. Wong, and S. Ferrone Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma Proc Natl Acad Sci U S A 89 1992 466 470
82. L. Mora-Garcia Mde, A. Duenas-Gonzalez, J. Hernandez-Montes, E. De la Cruz-Hernandez, E. Perez-Cardenas, and B. Weiss-Steider et al. Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid J Transl Med 4 2006 55
83. Y. Morimoto, M. Toyota, A. Satoh, M. Murai, H. Mita, and H. Suzuki et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells Br J Cancer 90 2004 844 852 (Pubitemid 38406596)
84. V. Nandakumar, M. Vaid, and S.K. Katiyar (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells Carcinogenesis 32 2011 537 544
85. A. Nebbioso, V. Carafa, R. Benedetti, and L. Altucci Trials with 'epigenetic' drugs: an update Mol Oncol 6 2012 657 682
86. H.J.S.L. Nicolay, E. Fonsatti, A. Covre, G. Parisi, E. Fratta, and S. Coral et al. Epigenetically regulated tumor-associated antigens in melanoma Expert Rev Dermatol 4 2009 10
87. Y. Nie, G. Yang, Y. Song, X. Zhao, C. So, and J. Liao et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas Carcinogenesis 22 2001 1615 1623 (Pubitemid 32952138)
88. Y. Oshimo, H. Nakayama, R. Ito, Y. Kitadai, K. Yoshida, and K. Chayama et al. Promoter methylation of cyclin D2 gene in gastric carcinoma Int J Oncol 23 2003 1663 1670
89. X. Peng, L. Pentassuglia, and D.B. Sawyer Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? Circ Res 106 2010 1022 1034
90. I.P. Pogribny Epigenetic events in tumorigenesis: putting the pieces together Exp Oncol 32 2010 132 136
91. S.M. Pollack, Y. Li, M.J. Blaisdell, E.A. Farrar, J. Chou, and B.L. Hoch et al. NYESO-1/LAGE-1 s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine PLoS One 7 2012 e32165
92. S. Qifeng, C. Bo, J. Xingtao, P. Chuanliang, and Z. Xiaogang Methylation of the promoter of human leukocyte antigen class I in human esophageal squamous cell carcinoma and its histopathological characteristics J Thorac Cardiovasc Surg 141 2011 808 814
93. M. Radosevich, M. Jager, and S.J. Ono Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator Exp Mol Pathol 82 2007 68 76 (Pubitemid 46038265)
94. M. Rao, N. Chinnasamy, J.A. Hong, Y. Zhang, M. Zhang, and S. Xi et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer Cancer Res 71 2011 4192 4204
95. K. Rao-Bindal, Z. Zhou, and E.S. Kleinerman MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts Cell Death Dis 3 2012 e369
96. F.J. Reu, S.I. Bae, L. Cherkassky, D.W. Leaman, D. Lindner, and N. Beaulieu et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation J Clin Oncol 24 2006 3771 3779 (Pubitemid 46622316)
97. F.J. Reu, D.W. Leaman, R.R. Maitra, S.I. Bae, L. Cherkassky, and M.W. Fox et al. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons Cancer Res 66 2006 2785 2793
98. M. Rodriguez-Paredes, and M. Esteller Cancer epigenetics reaches mainstream oncology Nat Med 17 2011 330 339
99. A. Satoh, M. Toyota, H. Ikeda, Y. Morimoto, K. Akino, and H. Mita et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells Oncogene 23 2004 8876 8886 (Pubitemid 39657778)
100. D.B. Scherf, N. Sarkisyan, H. Jacobsson, R. Claus, J.L. Bermejo, and B. Peil et al. Epigenetic screen identifies genotype-specific promoter DNA methylation and oncogenic potential of CHRNB4 Oncogene 32 2013 3329 3338
101. M. Schmudde, A. Braun, D. Pende, J. Sonnemann, U. Klier, and J.F. Beck et al. Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells Cancer Lett 272 2008 110 121
102. D.S. Schrump, M.R. Fischette, D.M. Nguyen, M. Zhao, X. Li, and T.F. Kunst et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura Clin Cancer Res 12 2006 5777 5785 (Pubitemid 44629609)
103. W.A. Schulz, J.P. Elo, A.R. Florl, S. Pennanen, S. Santourlidis, and R. Engers et al. Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma Genes Chromosomes Cancer 35 2002 58 65 (Pubitemid 34847869)
104. B. Seliger Molecular mechanisms of MHC class I abnormalities and APM components in human tumors Cancer Immunol Immunother 57 2008 1719 1726
105. A. Serrano, S. Tanzarella, I. Lionello, R. Mendez, C. Traversari, and F. Ruiz-Cabello et al. Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment Int J Cancer 94 2001 243 251 (Pubitemid 32911420)
106. A.F. Setiadi, M.D. David, R.P. Seipp, J.A. Hartikainen, R. Gopaul, and W.A. Jefferies Epigenetic control of the immune escape mechanisms in malignant carcinomas Mol Cell Biol 27 2007 7886 7894 (Pubitemid 350086422)
107. P. Sharma, K. Wagner, J.D. Wolchok, and J.P. Allison Novel cancer immunotherapy agents with survival benefit: recent successes and next steps Nat Rev Cancer 11 2011 805 812
108. L. Shen, M. Ciesielski, S. Ramakrishnan, K.M. Miles, L. Ellis, and P. Sotomayor et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models PLoS One 7 2012 e30815
109. L. Sigalotti, M. Altomonte, F. Colizzi, M. Degan, M. Rupolo, and V. Zagonel et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101 2003 4644 4646 (discussion 4645-4646) (Pubitemid 36857844)
110. L. Sigalotti, S. Coral, E. Fratta, E. Lamaj, R. Danielli, and A.M. Di Giacomo et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy Semin Oncol 32 2005 473 478 (Pubitemid 41396424)
111. L. Sigalotti, S. Coral, G. Nardi, A. Spessotto, E. Cortini, and I. Cattarossi et al. Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma J Immunother 25 2002 16 26 (Pubitemid 34052830)
112. L. Sigalotti, A. Covre, E. Fratta, G. Parisi, F. Colizzi, and A. Rizzo et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies J Transl Med 8 2010 56
113. L. Sigalotti, A. Covre, S. Zabierowski, B. Himes, F. Colizzi, and P.G. Natali et al. Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status J Cell Physiol 215 2008 287 291 (Pubitemid 351468940)
114. L. Sigalotti, E. Fratta, E. Bidoli, A. Covre, G. Parisi, and F. Colizzi et al. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients J Transl Med 9 2011 78
115. L. Sigalotti, E. Fratta, S. Coral, E. Cortini, A. Covre, and H.J. Nicolay et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications J Cell Physiol 212 2007 330 344 (Pubitemid 47025622)
116. L. Sigalotti, E. Fratta, S. Coral, S. Tanzarella, R. Danielli, and F. Colizzi et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine Cancer Res 64 2004 9167 9171 (Pubitemid 39665532)
117. J. Simova, V. Pollakova, M. Indrova, R. Mikyskova, J. Bieblova, and I. Stepanek et al. Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status Br J Cancer 105 2011 1533 1541
118. S. Skov, M.T. Pedersen, L. Andresen, P.T. Straten, A. Woetmann, and N. Odum Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B Cancer Res 65 2005 11136 11145 (Pubitemid 41713385)
119. J. Stingl, and C. Caldas Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis Nat Rev Cancer 7 2007 791 799 (Pubitemid 47463670)
120. B.D. Strahl, and C.D. Allis The language of covalent histone modifications Nature 403 2000 41 45 (Pubitemid 30038513)
121. C. Stresemann, B. Brueckner, T. Musch, H. Stopper, and F. Lyko Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines Cancer Res. 66 5 2006 Mar 1 2794-800
122. F. Sun, E. Chan, Z. Wu, X. Yang, V.E. Marquez, and Q. Yu Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells Mol Cancer Ther 8 2009 3191 3202
123. M. Tachibana, J. Ueda, M. Fukuda, N. Takeda, T. Ohta, and H. Iwanari et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9 Genes Dev 19 2005 815 826
124. K.F. Tang, C.X. He, G.L. Zeng, J. Wu, G.B. Song, and Y.S. Shi et al. Induction of MHC class I-related chain B (MICB) by 5-aza-2′-deoxycytidine Biochem Biophys Res Commun 370 2008 578 583
125. W.D. Thomas, and P. Hersey CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95) Int J Cancer 75 1998 384 390 (Pubitemid 28100040)
126. T.B. Tomasi, W.J. Magner, and A.N. Khan Epigenetic regulation of immune escape genes in cancer Cancer Immunol Immunother 55 2006 1159 1184 (Pubitemid 43992044)
127. C.R. Vakoc, S.A. Mandat, B.A. Olenchock, and G.A. Blobel Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin Mol Cell 19 2005 381 391 (Pubitemid 41074893)
128. E. Vire, C. Brenner, R. Deplus, L. Blanchon, M. Fraga, and C. Didelot et al. The Polycomb group protein EZH2 directly controls DNA methylation Nature 439 2006 871 874 (Pubitemid 43255707)
129. D.D. Vo, R.M. Prins, J.L. Begley, T.R. Donahue, L.F. Morris, and K.W. Bruhn et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824 Cancer Res 69 2009 8693 8699
130. C.H. Waddington The epigenotype. 1942 Int J Epidemiol 41 2012 10 13
131. I. Waldhauer, and A. Steinle NK cells and cancer immunosurveillance Oncogene 27 2008 5932 5943
132. J. Wang, S. Hevi, J.K. Kurash, H. Lei, F. Gay, and J. Bajko et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation Nat Genet 41 2009 125 129
133. P.M. Watt, R. Kumar, and U.R. Kees Promoter demethylation accompanies reactivation of the HOX11 proto-oncogene in leukemia Genes Chromosomes Cancer 29 2000 371 377
134. J. Weber, M. Salgaller, D. Samid, B. Johnson, M. Herlyn, and N. Lassam et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine Cancer Res 54 1994 1766 1771
135. T.S. Weiser, G.A. Ohnmacht, Z.S. Guo, M.R. Fischette, G.A. Chen, and J.A. Hong et al. Induction of MAGE-3 expression in lung and esophageal cancer cells Ann Thorac Surg 71 2001 295 301 (discussion 301-292)
136. F. Wischnewski, K. Pantel, and H. Schwarzenbach Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells Mol Cancer Res 4 2006 339 349 (Pubitemid 43837335)
137. J.D. Wolchok, J.S. Weber, M. Maio, B. Neyns, K. Harmankaya, and K. Chin et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials Ann Oncol 24 2013 2174 2180
138. A. Woloszynska-Read, P. Mhawech-Fauceglia, J. Yu, K. Odunsi, and A.R. Karpf Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated
139. K.L. Wright, and J.P. Ting Epigenetic regulation of MHC-II and CIITA genes Trends Immunol 27 2006 405 412 (Pubitemid 44216195)
140. K. Yamanegi, J. Yamane, K. Kobayashi, N. Kato-Kogoe, H. Ohyama, and K. Nakasho et al. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity Oncol Rep 24 2010 1621 1627
141. K. Yamanegi, J. Yamane, K. Kobayashi, N. Kato-Kogoe, H. Ohyama, and K. Nakasho et al. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death Int J Oncol 41 2012 83 91
142. D. Yang, C.M. Torres, K. Bardhan, M. Zimmerman, T.L. McGaha, and K. Liu Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo J Immunol 188 2012 4441 4449
143. Q. Ye, Y. Shen, X. Wang, J. Yang, F. Miao, and C. Shen et al. Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer Tissue Antigens 75 2010 30 39
144. C. Zhang, Y. Wang, Z. Zhou, J. Zhang, and Z. Tian Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis Cancer Immunol Immunother 58 2009 1275 1285
145. F. Zheng, A. Hasim, J. Anwer, M. Niyaz, and I. Sheyhidin LMP gene promoter hypermethylation is a mechanism for its down regulation in Kazak's esophageal squamous cell carcinomas Mol Biol Rep 40 2013 2069 2075